Biopharmaceutical firm, Suven Life Sciences Ltd. today said that the company has received two product patents, one from Japan and other from the US, for the New Chemical Entities (NCEs) indicated for treatment of disorders associated with Neurodegenerative diseases.
Valid through 2028 & 2029, the patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. With these 2 patents, Suven has a total of 6 granted patents from Japan and 12 from the US, the company said in a filing to the Bombay Stock Exchange.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders, the filing added.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally," Suven Life Sciences, CEO, Venkat Jasti said.